ATE59781T1 - Potenzierung von prazosin. - Google Patents

Potenzierung von prazosin.

Info

Publication number
ATE59781T1
ATE59781T1 AT87116236T AT87116236T ATE59781T1 AT E59781 T1 ATE59781 T1 AT E59781T1 AT 87116236 T AT87116236 T AT 87116236T AT 87116236 T AT87116236 T AT 87116236T AT E59781 T1 ATE59781 T1 AT E59781T1
Authority
AT
Austria
Prior art keywords
certain
relates
enhancement
prazosin
potentiation
Prior art date
Application number
AT87116236T
Other languages
English (en)
Inventor
Richard C Dage
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Application granted granted Critical
Publication of ATE59781T1 publication Critical patent/ATE59781T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT87116236T 1986-11-05 1987-11-04 Potenzierung von prazosin. ATE59781T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92778586A 1986-11-05 1986-11-05
EP87116236A EP0268146B1 (de) 1986-11-05 1987-11-04 Potenzierung von Prazosin

Publications (1)

Publication Number Publication Date
ATE59781T1 true ATE59781T1 (de) 1991-01-15

Family

ID=25455252

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87116236T ATE59781T1 (de) 1986-11-05 1987-11-04 Potenzierung von prazosin.

Country Status (11)

Country Link
EP (1) EP0268146B1 (de)
JP (1) JP2612175B2 (de)
KR (1) KR950013758B1 (de)
AT (1) ATE59781T1 (de)
DE (1) DE3767287D1 (de)
DK (1) DK167209B1 (de)
ES (1) ES2036560T3 (de)
GR (1) GR3001375T3 (de)
IE (1) IE59905B1 (de)
PH (1) PH23818A (de)
ZA (1) ZA878182B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2270517T3 (es) * 1997-05-19 2007-04-01 Zonagen, Inc. Terapia de combinacion para modular la respuesta sexual humana.
CN1282248A (zh) * 1997-12-16 2001-01-31 辉瑞产品公司 阳萎的联合治疗
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
EP1579862A1 (de) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Verwendung von PDE III Ihibitoren zur Reduktion der Herzgrösse in an Herzversagen leidenden Säugern
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1920785A1 (de) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Pimobendan-Cyclodextrin Komplex enthaltendes flüssiges Präparat
ES2924478T3 (es) 2012-03-15 2022-10-07 Boehringer Ingelheim Vetmedica Gmbh Formulación de comprimidos farmacéuticos para el sector médico veterinario, método de producción y uso de los mismos
US20130274245A1 (en) * 2012-04-11 2013-10-17 Jan BLUMENSTEIN Composition For Prevention of Vasoactivity in the Treatment of Blood Loss and Anemia
CN113181110A (zh) 2013-07-19 2021-07-30 勃林格殷格翰动物保健有限公司 含有防腐的醚化的环糊精衍生物的液体水性药物组合物
EP3106150B1 (de) 2013-12-04 2021-07-28 Boehringer Ingelheim Vetmedica GmbH Verbesserte pharmazeutische zusammensetzungen von pimobendan
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4130647A (en) * 1977-07-08 1978-12-19 Pfizer Inc. Methods for treating congestive heart failure and ischemic heart disease
US4601897A (en) * 1985-11-06 1986-07-22 Pfizer Inc. Prazosin-pirbuterol combination for bronchodilation

Also Published As

Publication number Publication date
JPS63132837A (ja) 1988-06-04
EP0268146B1 (de) 1991-01-09
EP0268146A1 (de) 1988-05-25
KR880005934A (ko) 1988-07-21
DK578887D0 (da) 1987-11-04
IE872975L (en) 1988-05-05
JP2612175B2 (ja) 1997-05-21
DE3767287D1 (de) 1991-02-14
DK167209B1 (da) 1993-09-20
KR950013758B1 (ko) 1995-11-15
IE59905B1 (en) 1994-04-20
PH23818A (en) 1989-11-23
ZA878182B (en) 1988-05-02
GR3001375T3 (en) 1992-09-11
ES2036560T3 (es) 1993-06-01
DK578887A (da) 1988-05-06

Similar Documents

Publication Publication Date Title
DE3751045D1 (de) Durch den Rhythmus gesteuerter Herzschrittmacher.
MA27113A1 (fr) Activateurs de glucokinase oxygenes cycloalkyle ou substitues cycloalkyle
FI946004A (fi) Lääketieteellisessä toimenpiteessä käytettävä trombiiniverifraktio
GR3022966T3 (en) Fluoro substituted benzocycloheptapyridine compounds, compositions and methods of use as antihistaminic compounds
ES2038826T3 (es) Estabilizadores organicos.
IS3284A7 (is) Aðferð við framleiðslu á N1-súbstitúeruðum bensimidasólafleiðum til að nota við lækningar
ATE59781T1 (de) Potenzierung von prazosin.
ES2037670T3 (es) Procedimiento para la preparacion de complejos de (2,2-bis(aminometil)-1,3-propanodiol-n,n') platino.
ATE39357T1 (de) Derivate von griseolicsaeure und ihre verwendung.
ATE91078T1 (de) Verwendung von melatonin oder seine derivate zur herstellung von arzneimitteln, die gegen alterskrankheiten wirksam sind.
ATE88349T1 (de) Hyperimmunizierte milch gegen bluthochdruck.
ES2058343T3 (es) Piridinas disubstituidas.
DK462687A (da) Forbindelse til behandling af retrovirusinfektioner.
DE3779777D1 (de) Aromatische verbindungen mit amider struktur, derivate von aminobenzoesaeuren, hydroxybenzoesaeuren, zimtsaeuren, urocansaeuren und benzimidazolen, die uvb und/oder uva absorbieren.
ATE69220T1 (de) Sechsgliedrige heterocyclische derivate von n'substituiertenn,n'-diacylhydrazinen.
ATE79615T1 (de) Cardiotonische phenyloxazolone.
NO903281L (no) S-substituerte beta-tioakrylamider og anvendelse derav sommikrobiocider.
SE7909787L (sv) Sett att framstella en antihemofilifaktor
ATE126437T1 (de) Verwendung von depogen zur behandlung von eingeschränktem blutkreislauf.
SE7909788L (sv) Sett att framstella en antihemofilifaktor
DE69807200D1 (de) Inklusionskomplexe in waessriger loesung
DE3774715D1 (de) Cardiotonische imidazolylphenylpyrrol-2-one.
ATE77952T1 (de) Verwendung von 1,4-dihydropyridinderivaten.
SU1432991A1 (ru) 4-Метил-5-(4-метилфениламино)-1,2,3-триазол, обладающий противовоспалительной активностью
ATE86863T1 (de) Verwendung von zusammensetzungen auf basis von crotoxin, zur herstellung von medikamenten zur behandlung von carcinomen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time